EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie

Prospective, Open‐Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics

Koji Kamiya iD, Yukie Yamaguchi iD, Hidehisa Saeki, Masanari Kodera, Yayoi Tada iD, Akimichi Morita iD, Masatoshi Abe, Yukari Okubo iD, Shigetoshi Sano iD, Mamitaro Ohtsuki iD

The Journal of Dermatology · 2026

DOI: 10.1111/1346-8138.17968 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Koji Kamiya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Jichi Medical University, Shimotsuke, Japan. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Biological Products, Phosphodiesterase 4 Inhibitors, Psoriasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although biologic agents have significantly improved therapeutic outcomes for psoriasis, their long‐term use can be burdensome for patients due to high costs, parenteral administration, and safety concerns. Consequently, some patients in remission wish to switch to alternative maintenance therapies to reduce this treatment burden. Based on our prior survey, the present prospective, open‐label, single‐arm, multicenter clinical study focused on patients with plaque psoriasis with or without psoriatic arthritis (PsA) who had achieved remission with biologics but were hesitant to continue this therapy. We evaluated the efficacy and safety of transitioning to apremilast, a phosphodiesterase 4 inhibitor, for maintaining remission. Among 209 patients initially surveyed, 46 were enrolled, and 44 were included in the efficacy analysis. The study cohort comprised 30 males and 16 females, with a mean disease duration of 19.2 years, a mean Psoriasis Area and Severity Index (PASI) score of 0.36, and a mean Dermatology Life Quality Index (DLQI) score of 0.30 at baseline. At 24 weeks, the Kaplan–Meier (KM) median time to relapse was not reached overall; the KM remission‐maintenance rate was 63.6% (95% CI, 48.8–76.3) when adverse event related discontinuations were counted as events, and 75.7% (59.7–86.8) when censored. The corresponding restricted mean survival time through 24 weeks was 20.31 and 22.03 weeks, respectively. Patients who maintained remission consistently demonstrated low scores (≤ 1) across PASI, Body Surface Area, DLQI, and American College of Rheumatology components throughout the observation period. A total of 34 adverse events occurred in 23 patients, most commonly diarrhea, vomiting, and headache. All were mild, no serious events were observed, and all resolved without sequelae. In conclusion, for patients with plaque psoriasis with or without PsA who have achieved remission but are concerned about the burdens of long‐term biologic therapy, transitioning to apremilast represents an effective and viable strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory Agents, Non-SteroidalBiological ProductsPhosphodiesterase 4 InhibitorsPsoriasisThalidomideAdultAgedFemaleHumansMaleMiddle AgedMaintenance ChemotherapyProspective StudiesQuality of LifeRecurrenceRemission InductionSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

Apremilastbiological productspsoriasisremission maintenancesafety management

Substanzen

Anti-Inflammatory Agents, Non-SteroidalapremilastBiological ProductsPhosphodiesterase 4 InhibitorsThalidomide

Autor:innen und Institutionen

  • Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
  • Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Department of Dermatology, Japan Community Health Care Organization (JCHO), Chukyo Hospital, Nagoya, Japan.
  • Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

ORCID-Profile: Koji Kamiya, Yukie Yamaguchi, Yayoi Tada, Akimichi Morita, Yukari Okubo, Shigetoshi Sano, Mamitaro Ohtsuki

Förderung

  • Amgen

Zitieren

APA

Kamiya, K., Yamaguchi, Y., Saeki, H., Kodera, M., Tada, Y., Morita, A., Abe, M., Okubo, Y., Sano, S., & Ohtsuki, M. (2026). Prospective, Open‐Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17968

Vancouver

Kamiya K, Yamaguchi Y, Saeki H, Kodera M, Tada Y, Morita A, et al. Prospective, Open‐Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.17968

BibTeX
@article{Kamiya2026,
  author = {Kamiya, Koji and Yamaguchi, Yukie and Saeki, Hidehisa and Kodera, Masanari and Tada, Yayoi and Morita, Akimichi and Abe, Masatoshi and Okubo, Yukari and Sano, Shigetoshi and Ohtsuki, Mamitaro},
  title = {Prospective, Open‐Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics},
  journal = {The Journal of Dermatology},
  year = {2026},
  doi = {10.1111/1346-8138.17968}
}
Kostenlos starten →